Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Pulse Biosciences, Inc.NASDAQ: PLSE

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $16.98M rose 40.4% year over year, ahead of the +27.3% change in trailing-twelve-month research & development. Sequentially, it rose 34.8% from the prior quarter. Over 3 fiscal years it compounded at +29.0% a year.

Context

  • Research & development amounted to 12777.4% of revenue in FY2025.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +40.4% holds above the trailing-twelve-month pace of +27.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$16.98M+34.8% QoQ
Last fiscal yearDec 2025
$44.72M+38.3% YoY
LTMJun 2026
$51.89M+27.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.4%——
1 year+38.3%——
3-year CAGR+29.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
44.72M USD
Year-over-year change
+38.3%
4-year CAGR
+11.8%

Research & Development vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +27.3% is the 6th highest of 11, against a peer median of +17.8%.
  • Research & development amounts to 4378.6% of revenue for PLSE, versus a peer median of 34.0%.
PLSE Competitors
Research & Development for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$229.1M USD+8.2%+2.9%34.0%
IMTXImmatics N.V.LTM Mar 2026€201.11M EUR+27.4%+19.9%539.2%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$175.6M USD+66.9%+70.5%9222.6%
NKTRNektar TherapeuticsLTM Jun 2026$131.77M USD+6.1%-18.7%241.4%
OPKOPKO Health, Inc.LTM Mar 2026$122.39M USD+7.2%+18.8%21.1%
ATAIAtai Beckley Inc.LTM Jun 2026$79.04M USD+47.5%-10.6%1767.0%
PLSEPulse Biosciences, Inc.LTM Jun 2026$51.89M USD+27.3%+29.0%4378.6%
STAASTAAR Surgical CompanyLTM Apr 2026$38.43M USD-26.2%+3.6%13.2%
BBNXBeta Bionics, Inc.LTM Mar 2026$37.56M USD+32.7%+3.4%34.1%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$19.24M USD+36.6%—23.0%
LFMDLifeMD, Inc.LTM Mar 2026$7.53M USD-25.4%+35.2%3.4%
Peer median (excluding PLSE) —+17.8%+3.6%34.0%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.42M700K00350K
Cost of Revenue1.97M11.94M1.21M01.61M
Gross Profit(550K)(11.24M)(1.21M)0(1.26M)
Gross Margin-38.8%-1606.3%——-360.0%
Research & Development28.64M20.84M27.8M32.34M44.72M
Selling, General & Admin33.82M25.97M15.78M23.92M32.03M
Operating Expenses62.46M46.81M42.37M56.26M75.68M
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
EBITDA(62.51M)(57.15M)(39.9M)(52.41M)(71.71M)
EBITDA Margin-4408.6%-8164.3%——-20488.6%
Operating Income(63.01M)(58.06M)(43.57M)(56.26M)(76.94M)
Operating Margin-4443.9%-8293.9%——-21982.6%
Interest Income002.46M2.67M4.21M
Interest Expense646K448K1.1M00
Other Income / Expenses(646K)(448K)1.36M2.67M4.16M
Income Before Tax(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Pre-Tax Margin-4489.4%-8357.9%——-20794.6%
Income Tax Expense00000
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Net Margin-4489.4%-8357.9%——-20794.6%
EPS (Basic)(2.28)(1.72)(0.88)(0.92)(1.08)
EPS (Diluted)(2.28)(1.72)(0.88)(0.92)(1.08)
Weighted Avg Shares27.96M33.94M48.04M58.4M67.4M
Weighted Avg Shares (Diluted)27.96M33.94M48.04M58.4M67.4M

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.